Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

M-16049: hypoglycemic agent and aldose reductase inhibitor

June 12, 1997

Otsuka AGE inhibitor prevents progression of diabetic nephropathy in animal model

June 12, 1997

Novel site of action for chimeric insulin-releasing peptide

June 12, 1997

BRL-48482 has potential for reducing cardiovascular risk in NIDDM

June 12, 1997

Phase III results for AY-4166

June 12, 1997

Pioglitazone improves insulin resistance in NIDDM

June 12, 1997

New preclinical studies on JTT-501

June 12, 1997

Clinical results in NIDDM reported for troglitazone

June 12, 1997

Efficacy of pioglitazone demonstrated in NIDDM patients

June 11, 1997

Miglitol tested in specific population subgroups

June 11, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...